Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
This article was originally published in The Tan Sheet
Executive Summary
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company
You may also be interested in...
Zyrtec-D Paragraph IV Application Submitted To FDA
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer
Zyrtec-D Paragraph IV Application Submitted To FDA
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer
Zyrtec-D Paragraph IV Application Submitted To FDA
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer